Silence is the only listed RNAi player in Europe and a pioneer in this technology. Through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger RNAi in specific cell types. Our inventions are protected by a broad intellectual property estate, which is a fundamental asset. Together with our progress, the fact that the field is generally maturing means that RNAi drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients.
Annual Report 2018Download
Full Year Results 2019361KB Download
Half Year Results 2019345KB Download
Full Year Results 2018371KB Download
Half Year Results 2018367KB Download
Full Year Results 2017298KB Download
Annual Report 20191MB Download
Annual Report 20183MB Download
Annual Report 20172MB Download
Annual Report 20161MB Download
Annual Report 2015978KB Download
Silence Therapeutics FY19 Results Announcement175KB Download
Collaboration with AstraZeneca and R&D Update176KB Download
Silence Therapeutics Fireside Chat at the RBC Capital Markets Global Healthcare Virtual Conference163KB Download
Silence Therapeutics Virtual Presentation at the Annual Needham Healthcare Conference - Live webcast1MB Download
Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics for Cardiovascular, Renal, Metabolic and Respiratory Diseases - Live presentation and Q&A509KB Download
Our Corporate Governance framework is based on using the leadership provided by our Board to drive the effective execution of our strategy, ensuring that risk is appropriately mitigated and managed.
We have three Board Committees (Remuneration, Audit and Risk, and Nominations), focused on providing the required oversight to maintaining the highest Corporate Governance standards. Through these committees and regular interactions with the executive team, our Board applies internal financial controls and approves the Company’s policy and strategy.